Literature DB >> 8985336

Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

Y H Chow1, W L Huang, W K Chi, Y D Chu, M H Tao.   

Abstract

DNA vaccines encoding a viral protein have been shown to induce antiviral immune responses and provide protection against subsequent viral challenge. In this study, we show that the efficacy of a DNA vaccine can be greatly improved by simultaneous expression of interleukin-2 (IL-2). Plasmid vectors encoding the major (S) or middle (pre-S2 plus S) envelope proteins of hepatitis B virus (HBV) were constructed and compared for their potential to induce hepatitis B surface antigen (HBsAg)-specific immune responses with a vector encoding the middle envelope and IL-2 fusion protein or with a bicistronic vector separately encoding the middle envelope protein and IL-2. Following transfection of cells in culture with these HBV plasmid vectors, we found that the encoded major protein was secreted while the middle protein and the fusion protein were retained on the cell membrane. Despite differences in localization of the encoded antigens, plasmids encoding the major or middle proteins gave similar antibody and T-cell proliferative responses in the vaccinated animals. The use of plasmids coexpressing IL-2 and the envelope protein in the fusion or nonfusion context resulted in enhanced humoral and cellular immune responses. In addition, the vaccine efficacy in terms of dosage used in immunization was increased at least 100-fold by coexpression of IL-2. We also found that DNA vaccines coexpressing IL-2 help overcome major histocompatibility complex-linked nonresponsiveness to HBsAg vaccination. The immune responses elicited by HBV DNA vaccines were also modulated by coexpression of IL-2. When restimulated with antigen in vitro, splenocytes from mice that received plasmids coexpressing IL-2 and the envelope protein produced much stronger T helper 1 (Th1)-like responses than did those from mice that had been given injections of plasmids encoding the envelope protein alone. Coexpression of IL-2 also increased the Th2-like responses, although the increment was much less significant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985336      PMCID: PMC191037     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

2.  DNA vaccination against persistent viral infection.

Authors:  L P Martins; L L Lau; M S Asano; R Ahmed
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection.

Authors:  M Yokoyama; J Zhang; J L Whitton
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

5.  Induction of antibodies to a kappa V region by gene immunization.

Authors:  A Watanabe; E Raz; H Kohsaka; H Tighe; S M Baird; T J Kipps; D A Carson
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

6.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

7.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

Authors:  K R Irvine; J B Rao; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

8.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.

Authors:  M L Michel; H L Davis; M Schleef; M Mancini; P Tiollais; R G Whalen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

9.  Immune responses to nucleic acid vaccines to rabies virus.

Authors:  Z Q Xiang; S L Spitalnik; J Cheng; J Erikson; B Wojczyk; H C Ertl
Journal:  Virology       Date:  1995-06-01       Impact factor: 3.616

10.  Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).

Authors:  N Osterrieder; R Wagner; C Brandmüller; P Schmidt; H Wolf; O R Kaaden
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  34 in total

1.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

2.  Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Authors:  J J Kim; J S Yang; T C VanCott; D J Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Genetic vaccines: strategies for optimization.

Authors:  G Gregoriadis
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 4.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

Review 5.  DNA gene vaccination for HIV.

Authors:  J J Kim; D B Weiner
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.

Authors:  S Sasaki; K Hamajima; J Fukushima; A Ihata; N Ishii; I Gorai; F Hirahara; H Mohri; K Okuda
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.

Authors:  A Rainczuk; T Scorza; T W Spithill; P M Smooker
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.

Authors:  Hui Hu; Xinya Lu; Ling Tao; Bingke Bai; Zhenfeng Zhang; Yao Chen; Fangliang Zheng; Jianjun Chen; Ze Chen; Hanzhong Wang
Journal:  Clin Vaccine Immunol       Date:  2007-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.